Below are the financial statements of Rohto Pharmaceutical, including the income statement and balance sheet for the company's latest fiscal year. All figures are accurate, verifiable, and fully traceable to the original annual filing where disclosed.
| All figures in billions of JPY | 2024 | 2023 |
|---|---|---|
| Net sales | 270.84a | 238.66a |
| Cost of sales | -113.55a | -101.24a |
| Gross profit | 157.29a | 137.42a |
| Selling, general and administrative expenses | — | — |
| Promotion expenses | -16.24a | -14.42a |
| Advertising expenses | -37.98a | -32.05a |
| Salaries and bonuses | -19.81a | -18.28a |
| Provision for bonuses | -1.53a | -1.51a |
| Provision for bonuses for directors (and other officers) | -0.05a | -0.05a |
| Retirement benefit expenses | -0.62a | -0.63a |
| Depreciation | -1.99a | -1.96a |
| Amortization of goodwill | -0.44a | -0.38a |
| Research and development expenses | -13.39a | -11.07a |
| Provision of allowance for doubtful accounts | -0.05a | -0.2a |
| Other | -25.15a | -22.92a |
| Total selling, general and administrative expenses | -117.24a | -103.46a |
| Operating profit | 40.05a | 33.96a |
| Non-operating income | — | — |
| Interest income | 1.52a | 0.96a |
| Dividend income | 0.49a | 0.46a |
| Share of profit of entities accounted for using equity method | 0a | 0.06a |
| Foreign exchange gains | 0.45a | 0.35a |
| Reversal of allowance for doubtful accounts | 0.12a | 0a |
| Gain on investments in investment partnerships | 0a | 0.86a |
| Other | 0.97a | 1.01a |
| Total non-operating income | 3.55a | 3.7a |
| Non-operating expenses | — | — |
| Interest expenses | -0.2a | -0.25a |
| Share of loss of entities accounted for using equity method | -0.29a | 0a |
| Loss on investments in investment partnerships | -0.21a | 0a |
| Provision of allowance for doubtful accounts | 0a | -0.42a |
| Donations | 0a | -1a |
| Other | -0.47a | -0.42a |
| Total non-operating expenses | -1.16a | -2.09a |
| Ordinary profit | 42.43a | 35.57a |
You are welcome to quote or reference individual data points from this page, provided you include the following attribution with a visible, clickable link to this page: "Source: Tracenable, the global reference for ESG data"
Bulk collection, scraping, resale, or redistribution of data across multiple company profiles is not permitted without our prior written permission. For more information, see our General Terms and Conditions.
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform.